Glenmark Pharmaceuticals gains on reporting 21% rise in Q1 consolidated net profit
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Glenmark Pharmaceuticals is currently trading at Rs. 566.20, up by 3.00 points or 0.53% from its previous closing of Rs. 563.20 on the BSE.
The scrip opened at Rs. 567.25 and has touched a high and low of Rs. 576.50 and Rs. 561.90 respectively. So far 46661 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 690.60 on 19-Jul-2021 and a 52 week low of Rs. 441.65 on 22-Sep-2020.
Last one week high and low of the scrip stood at Rs. 597.65 and Rs. 560.20 respectively. The current market cap of the company is Rs. 15891.71 crore.
The promoters holding in the company stood at 46.63%, while Institutions and Non-Institutions held 36.55% and 16.82% respectively.
Glenmark Pharmaceuticals has reported 5.83% rise in its net profit at Rs 489.42 crore for the quarter ended June 30, 2021 as compared to Rs 462.48 crore for the same quarter in the previous year. Total income of the company increased by 25.45% at Rs 2280.33 crore for Q1FY22 as compared Rs 1817.77 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported rise of 20.66% in its net profit at Rs 306.53 crore for the quarter under review as compared to Rs 254.04 crore for the same quarter in the previous year. Total income of the company marginally increased by 25.81% at Rs 3023.54 crore for Q1FY22 as compared Rs 2403.30 crore for the corresponding quarter previous year.
